Bio-Techne (TECH) Form 4 BIO-TECHNE / James Hippel ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hippel James

(Last) (First) (Middle)

614 MCKINLEY PLACE N.E.

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2016

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2016		M		1,666	A	(1)	6,100(2)	D
Common Stock	03/31/2016		F		556	D	$94.52	5,544	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/31/2016		M			1,666	(3)	(3)	Common Stock	1,666	$0.00	1,667	D
Restricted Stock Units	(1)							(4)	(4)	Common Stock	3,000		3,000	D
Stock Options (Right to Buy)	$108.49							(4)	08/07/2022	Common Stock	12,500		12,500	D
Stock Options (Right to buy)	$108.49							(5)	08/07/2022	Common Stock	25,000		25,000	D
Stock Options (Right to Buy)	$94.35							(6)	08/12/2021	Common Stock	35,000		35,000	D
Stock Options (Right to Buy)	$86.25							(7)	04/01/2021	Common Stock	10,000		10,000	D
Stock Options (Right to buy)	$86.25							(8)	04/01/2021	Common Stock	25,000		25,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

2. Includes 1,667 shares of restricted stock units that vest on 3/31/2017 (previously reported on Table II).

3. On April 1, 2014, the reporting person was granted 5,000 restricted stock units, vesting in three equal annual installments beginning on March 31,2015.

4. Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.

5. 6,250 shares vest on each of 8/7/2016, 8/7/2017, 8/7/2018 and 8/7/2019.

6. 8,750 shares vest on each of 8/12/2015, 8/12/2016, 8/12/2017 and 8/12/2018.

7. Vests in full or in part if certain performance goals are achieved.

8. 6,250 shares vest on each of 4/1/2015, 4/1/2016, 4/1/2017 and 4/1/2018.

Remarks:

	/s/ Elizabeth M. Dunshee as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed.	04/04/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.